Harvard Bioscience to Present at Sidoti Investor Conference March 22-23, 2023
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) announced that CEO Jim Green will present at the Sidoti Virtual Investor Conference on March 22-23, 2023. He is scheduled to present on March 22 at 10:00 AM ET, and a live webcast will be accessible through their website. The presentation will also be archived for a limited time. Additionally, the company will facilitate one-on-one meetings with investors on both days.
Details
News Market Reaction – HBIO
The recorded move for HBIO in the trading session of this news was +7.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023.
Mr. Green will present on Wednesday, March 22 at 10:00 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.
Harvard Bioscience will also host virtual one-on-one meetings with investors on Wednesday and Thursday, March 22-23, 2023.
To register for the presentation or to schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact:
Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
investors@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.